XML 112 R11.htm IDEA: XBRL DOCUMENT v3.19.3
Revenues Revenues
 9 Months Ended
Sep. 30, 2019
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
Product Revenues
Revenues by product are summarized as follows:
 
For the Three Months
Ended September 30,
(In millions)
2019
 
2018
 
United
States
 
Rest of
World
 
Total
 
United
States
 
Rest of
World
 
Total
Multiple Sclerosis (MS):
 
 
 
 
 
 
 
 
 
 
 
TECFIDERA
$
842.0

 
$
280.4

 
$
1,122.4

 
$
842.1

 
$
247.9

 
$
1,090.0

Interferon*
360.3

 
169.7

 
530.0

 
421.5

 
168.6

 
590.1

TYSABRI
263.0

 
220.6

 
483.6

 
253.0

 
217.2

 
470.2

FAMPYRA
—

 
24.2

 
24.2

 
—

 
22.5

 
22.5

Subtotal: MS product revenues
1,465.3

 
694.9

 
2,160.2

 
1,516.6

 
656.2

 
2,172.8

 
 
 
 
 
 
 
 
 
 
 
 
Spinal Muscular Atrophy:
 
 
 
 

 
 
 
 
 

SPINRAZA
236.7

 
310.4

 
547.1

 
223.9

 
243.8

 
467.7

 
 
 
 
 
 
 
 
 
 
 
 
Biosimilars:
 
 
 
 

 
 
 
 
 

BENEPALI
—

 
115.9

 
115.9

 
—

 
123.4

 
123.4

IMRALDI
—

 
49.3

 
49.3

 
—

 
—

 
—

FLIXABI
—

 
18.4

 
18.4

 
—

 
11.4

 
11.4

Subtotal: Biosimilar product revenues
—

 
183.6

 
183.6

 
—

 
134.8

 
134.8

 
 
 
 
 
 
 
 
 
 
 
 
Other:
 
 
 
 
 
 
 
 
 
 
 
FUMADERM
—

 
3.8

 
3.8

 
—

 
4.8

 
4.8

Total product revenues
$
1,702.0

 
$
1,192.7

 
$
2,894.7

 
$
1,740.5

 
$
1,039.6

 
$
2,780.1

*Interferon includes AVONEX and PLEGRIDY.
 
For the Nine Months
Ended September 30,
(In millions)
2019
 
2018
 
United
States
 
Rest of
World
 
Total
 
United
States
 
Rest of
World
 
Total
Multiple Sclerosis (MS):
 
 
 
 
 
 
 
 
 
 
 
TECFIDERA
$
2,429.5

 
$
841.9

 
$
3,271.4

 
$
2,396.8

 
$
766.9

 
$
3,163.7

Interferon*
1,067.3

 
518.0

 
1,585.3

 
1,237.5

 
528.4

 
1,765.9

TYSABRI
772.3

 
647.0

 
1,419.3

 
768.2

 
631.3

 
1,399.5

FAMPYRA
—

 
71.2

 
71.2

 
—

 
69.9

 
69.9

ZINBRYTA
—

 
—

 
—

 
—

 
1.4

 
1.4

Subtotal: MS product revenues
4,269.1

 
2,078.1

 
6,347.2

 
4,402.5

 
1,997.9

 
6,400.4

 
 
 
 
 
 
 
 
 
 
 
 
Spinal Muscular Atrophy:
 
 
 
 
 
 
 
 
 
 
 
SPINRAZA
690.6

 
863.2

 
1,553.8

 
617.8

 
636.5

 
1,254.3

 
 
 
 
 
 
 
 
 
 
 
 
Biosimilars:
 
 
 
 
 
 
 
 
 
 
 
BENEPALI
—

 
360.2

 
360.2

 
—

 
359.9

 
359.9

IMRALDI
—

 
132.3

 
132.3

 
—

 
—

 
—

FLIXABI
—

 
49.9

 
49.9

 
—

 
29.2

 
29.2

Subtotal: Biosimilar product revenues
—

 
542.4

 
542.4

 
—

 
389.1

 
389.1

 
 
 
 
 
 
 
 
 
 
 
 
Other:
 
 
 
 
 
 
 
 
 
 
 
FUMADERM
—

 
11.6

 
11.6

 
—

 
17.3

 
17.3

Total product revenues
$
4,959.7

 
$
3,495.3

 
$
8,455.0

 
$
5,020.3

 
$
3,040.8

 
$
8,061.1


*Interferon includes AVONEX and PLEGRIDY.
We recognized revenues from two wholesalers accounting for 28.7% and 18.4% of gross product revenues for the three months ended September 30, 2019, and 30.1% and 17.0% of gross product revenues for the nine months ended September 30, 2019.
We recognized revenues from two wholesalers accounting for 30.7% and 19.3% of gross product revenues for the three months ended September 30, 2018, and 32.4% and 18.0% of gross product revenues for the nine months ended September 30, 2018.
An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions)
Discounts
 
Contractual
Adjustments
 
Returns
 
Total
Balance, as of December 31, 2018
$
127.8

 
$
888.8

 
$
34.7

 
$
1,051.3

Current provisions relating to sales in current year
480.3

 
2,149.7

 
16.1

 
2,646.1

Adjustments relating to prior years
(0.4
)
 
(46.7
)
 
4.6

 
(42.5
)
Payments/credits relating to sales in current year
(349.3
)
 
(1,510.0
)
 
(0.7
)
 
(1,860.0
)
Payments/credits relating to sales in prior years
(129.3
)
 
(564.4
)
 
(15.4
)
 
(709.1
)
Balance, as of September 30, 2019
$
129.1

 
$
917.4

 
$
39.3

 
$
1,085.8


The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:
(In millions)
As of
September 30,
2019
 
As of
December 31,
2018
Reduction of accounts receivable, net
$
201.6

 
$
176.6

Component of accrued expenses and other
884.2

 
874.7

Total revenue-related reserves
$
1,085.8

 
$
1,051.3


Revenues from Anti-CD20 Therapeutic Programs
Revenues from anti-CD20 therapeutic programs are summarized as follows:
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
(In millions)
2019
 
2018
 
2019
 
2018
Biogen’s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA
$
393.2

 
$
358.0

 
$
1,161.2

 
$
1,066.6

Other revenues from anti-CD20 therapeutic programs
202.6

 
153.7

 
528.4

 
378.7

Total revenues from anti-CD20 therapeutic programs
$
595.8

 
$
511.7

 
$
1,689.6

 
$
1,445.3


For additional information on our collaboration arrangements with Genentech, please read Note 19, Collaborative and Other Relationships, to our consolidated financial statements included in our 2018 Form 10-K.
Other Revenues
Other revenues are summarized as follows:
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
(In millions)
2019
 
2018
 
2019
 
2018
Revenues from collaborative and other relationships:
 
 
 
 
 
 
 
(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie
$
0.3

 
$
(0.7
)
 
$
(0.2
)
 
$
(7.9
)
Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis
12.9

 
48.1

 
89.9

 
80.7

Other royalty and corporate revenues:
 
 
 
 


 


Royalty
3.3

 
7.9

 
9.9

 
35.8

Other corporate
93.1

 
91.9

 
462.4

 
311.6

Total other revenues
$
109.6

 
$
147.2

 
$
562.0

 
$
420.2


Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ Inc. (Bioverativ). During the three and nine months ended September 30, 2019, we recognized $65.6 million and $306.9 million, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business, compared to $36.5 million and $131.1 million, respectively, in the prior year comparative periods.
During the third quarter of 2019 we amended our agreement with a contract manufacturing customer. Under the amended agreement, we will license certain of our manufacturing-related intellectual property to the customer. We will be eligible to receive $500.0 million in a series of three payments. The first payment is due upon a regulatory achievement related to the customer’s product manufactured using our manufacturing-related intellectual property, with subsequent payments payable upon the first and second anniversaries of the regulatory achievement. We do not expect to recognize any amounts related to this arrangement in 2019 as we do not expect the regulatory achievement to occur until 2020. If we earn this payment, we expect to allocate the consideration between the license for the manufacturing-related intellectual property and the manufacturing product supply services.
For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 17, Collaborative and Other Relationships, to these condensed consolidated financial statements. For additional information on our collaboration arrangement with AbbVie Inc., please read Note 19, Collaborative and Other Relationships, to our consolidated financial statements included in our 2018 Form 10-K. For additional information on our manufacturing and supply agreement with Bioverativ, please read Note 3, Hemophilia Spin-Off, to our consolidated financial statements included in our 2018 Form 10-K.